Subclinical primary aldosteronism is an under-recognized driver of cardiovascular risk. Could it be a new target for CV prevention? Read our Circulation editorial —>

Such a great opportunity, to be involved in an editorial on the most recent evidence for Subclinical Primary Aldosteronism. Thank you to @drwanpen.bsky.social @giaconajohn.bsky.social

Go check it out!! www.ahajournals.org/doi/10.1161/...

Great dinner celebrating #Hypertension25 together near harbor with UTSW group Angie Price @giaconajohn.bsky.social @robynwei.bsky.social @jesslin23.bsky.social and Mu Huang

Thank you to AHA for the opportunity to present at AHA HTN scientific session 25 in Baltimore. Having an amazing time meeting and connecting with experts in the field! @drwanpen.bsky.social @giaconajohn.bsky.social
@robynwei.bsky.social

Great talk #Hypertension25 by @jesslin23.bsky.social in discussing limitations of visual estimation of home BP in clinical decision in Rx HTN in Eyeball study @robynwei.bsky.social @giaconajohn.bsky.social

Got to Baltimore #Hypertension25 so excited to see friends and colleagues talking about high BP ! @ahascience.bsky.social @giaconajohn.bsky.social

Another fun Hypertension JC today. Bedmed trial was disccused by Jesslin Abraham our fellow. @giaconajohn.bsky.social @hkkimphd.bsky.social @utswim.bsky.social

Join us @jordybc.bsky.social , Keith Ferdinand, and Dan Jones unpacking 2025 AHA/ACC guidelines on Thursday Aug 28 bit.ly/Guideline25W... @UTSWInternalMed @utswheart